ArticleProceedings of the National Academy of Sciences of the United States of America2022

Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.

Joshua A Korsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.